Giorgia Vicentini
Vice President, Program Lead, Oncology Bristol Myers Squibb
Seminars
Wednesday 14th October 2026
Spotlighting the Clinical Performance of Izalontamab Brengitecan Bispecific ADC
4:00 pm
- Breaking down design and development of Iza-Bren, a EGFR/HER3 bispecific ADC, including advantages against traditional monospecific ADC therapies
- Evaluating Iza-Bren clinical profile based on recent clinical trials
- Laying out ongoing clinical development of Iza-Bren through bispecific ADC advantages and impactful clinical profile
